Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial - Fangusaro, J; Onar-Thomas, A; Young Poussaint, T (Lancet Oncol, 2019)